Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
No marketing; no money. It's been four weeks since the approval of MannKind's novel inhalable insulin, Afrezza, and the company has yet to find a marketing partner. The drug's failure to launch illustrates the difficulties in post-approval market access—even with an innovative product.
After 10 years jumping through regulatory hurdles (which included two outright rejections), Afrezza's approval was greeted by some as the inflection point MannKind needed for its fast-acting insulin. And while the rapid-acting segment has not been as successful as the long-acting insulins (Sanofi's Lantus is the best-selling diabetes drug), MannKind expected Afrezza's unique mechanism of action to grow the pie—especially with diabetes prevalence on the rise.
http://www.mmm-online.com/lack-of-marketing-partner-delays-afrezza-launch/article/363204/
A dead duck, methinks...🙄
After 10 years jumping through regulatory hurdles (which included two outright rejections), Afrezza's approval was greeted by some as the inflection point MannKind needed for its fast-acting insulin. And while the rapid-acting segment has not been as successful as the long-acting insulins (Sanofi's Lantus is the best-selling diabetes drug), MannKind expected Afrezza's unique mechanism of action to grow the pie—especially with diabetes prevalence on the rise.
http://www.mmm-online.com/lack-of-marketing-partner-delays-afrezza-launch/article/363204/
A dead duck, methinks...🙄